PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.97%
Revenue growth 1.25-1.5x MRVL's 1.55%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
4.02%
Gross profit growth above 1.5x MRVL's 1.76%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
9.76%
EBIT growth above 1.5x MRVL's 1.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
9.76%
Operating income growth above 1.5x MRVL's 1.27%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
4.97%
Net income growth above 1.5x MRVL's 0.46%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
5.26%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
1.75%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
1.63%
Share count expansion well above MRVL's 2.72%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.89%
Diluted share count expanding well above MRVL's 3.72%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-107.79%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-148.16%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
352.22%
10Y revenue/share CAGR under 50% of MRVL's 736.89%. Michael Burry would suspect a lasting competitive disadvantage.
53.06%
5Y revenue/share CAGR at 50-75% of MRVL's 104.05%. Martin Whitman would worry about a lagging mid-term growth trajectory.
13.23%
3Y revenue/share CAGR at 50-75% of MRVL's 23.48%. Martin Whitman would question if the firm lags behind competitor innovations.
-134.04%
Negative 10Y OCF/share CAGR while MRVL stands at 2041.57%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-105.37%
Negative 5Y OCF/share CAGR while MRVL is at 222.70%. Joel Greenblatt would question the firm’s operational model or cost structure.
-101.68%
Negative 3Y OCF/share CAGR while MRVL stands at 332.41%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
404.31%
Below 50% of MRVL's 2787.12%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
90.46%
Below 50% of MRVL's 181.77%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-0.72%
Negative 3Y CAGR while MRVL is 456.99%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1080.32%
Below 50% of MRVL's 9943.30%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
107.36%
5Y equity/share CAGR above 1.5x MRVL's 58.40%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
30.25%
3Y equity/share CAGR at 75-90% of MRVL's 33.72%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.26%
AR growth well above MRVL's 25.76%. Michael Burry fears inflated revenue or higher default risk in the near future.
17.38%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
6.05%
Similar asset growth to MRVL's 5.99%. Walter Schloss finds parallel expansions or investment rates.
5.61%
BV/share growth above 1.5x MRVL's 3.56%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.44%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
0.86%
R&D dropping or stable vs. MRVL's 2.86%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.05%
SG&A growth well above MRVL's 3.15%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.